PROTAGENIC THERAPEUTICS, INC. (OTCMKTS:PTIX) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearItem 5.03. Amendments to Articles of Incorporation or Bylaws.
On May 31, 2018, the Board of Directors of Protagenic Therapeutics, Inc. (the “Company”) adopted Second Amended and Restated Bylaws (“New Bylaws”), which became effective immediately upon adoption and amended and restated the Company’s then-existing Bylaws (“Old Bylaws”). The New Bylaws are intended to permit the Board to hold a virtual stockholder meeting by means of remote communication if the Board determines to do so. To provide greater clarity, the Board amended Section 1 of the Old Bylaws by adding a new subsection (b). This summary is qualified by reference to the complete text of the New Bylaws attached as Exhibit 3.1 hereto and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
*Filed herewith.
Protagenic Therapeutics, Inc.new ExhibitEX-3.1 2 ex3-1.htm SECOND AMENDED AND RESTATED BYLAWS OF PROTAGENIC THERAPEUTICS,…To view the full exhibit click here
About PROTAGENIC THERAPEUTICS, INC. (OTCMKTS:PTIX)
Protagenic Therapeutics, Inc., formerly Atrinsic, Inc., is a development-stage company. The Company is a biotechnology company that specializes in the discovery and development of therapeutics to treat central nervous system (CNS) disorders. The Company provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-base, brain active therapeutics. The Company has developed a portfolio of neuropeptides that are in various stages of development and preclinical evaluation for the treatment of various mood disorders. These neuropeptides are called PT00114, PT00121, PT00211, PT00311 and PT00411. As of September 30, 2016, the Company has not generated any revenue.
